After regulators approved Soleno Therapeutics Inc.'s nearly half-million-a-year drug to treat an insatiable, dangerous hunger in people with a rare genetic disease, the Redwood City company's ...

Shares of Solano Therapeutics are surging after winning US FDA approval for its new drug to treat excessive hunger and people with Prader-Willi syndrome, a genetic disorder that leads to physical ...

Scientists have a radical new plan for controlling mosquito numbers and fighting malaria: lacing human blood with a drug that's poisonous for the ... Nitisinone already has regulatory approval for ...

Thursday marks 27 years since the U.S. Food and Drug Administration approved the sale of Viagra, the nation’s first oral medication for what’s now commonly known as erectile dysfunction.

The Food and Drug Administration (FDA) has approved a new drug, Blujepa, the first of a new class of oral antibiotics for treating UTIs, to head to market. Drugmaker GSK plans to release the ...

which Leerink Partners’ Joseph Schwartz noted was greater than Sarepta Therapeutics showed with its Elevidys gene therapy, which the FDA approved in 2023.

The Food and Drug Administration on Wednesday approved the first treatment for the insatiable hunger associated with the rare disease Prader-Willi syndrome, a long-awaited decision that follows an ...

On March 26, 2025, the new drug application (NDA) for diazoxide choline extended-release tablets (VYKAT XR; Soleno Therapeutics) was approved by the FDA to treat hyperphagia among individuals aged 4 ...

TUESDAY, March 25, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women ...

The implantable vascular conduit, which is indicated for arterial injury, won FDA approval in December 2024. Symvess is intended for use in both hospitals and for military use. Although repairing ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...

today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection.